<i>ROS1</i> fusion-positive non-small cell lung cancer-repotrectinib as a new treatment option.

ABSTRACT:

SUBMITTER: Rothschild SI 

PROVIDER: S-EPMC12268506 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature